Paco De Arcos

Researchers are studying children with advanced, relapsed, or refractory melanoma, solid tumors, and lymphomas. The trial aims to learn if different doses of pembrolizumab, an immunotherapy that helps the immune system fight cancer, can shrink or eliminate these cancers. Some groups of children are no longer enrolling due to amendments during the study. Participants receive pembrolizumab through an intravenous IV infusion every three weeks. The study includes different groups based on the type of cancer and age, such as melanoma, solid tumors, relapsed refractory classical Hodgkin lymphoma, and certain high-risk melanoma stages. Enrollment for some groups has closed over time as the study progressed. During the study, participants will have their cancer measured using established criteria and monitored for side effects and responses for up to two years. Researchers will assess tumor response, progression-free survival, overall survival, and duration of response. Safety is tracked through adverse event reporting and dose-limiting toxicity monitoring. The trial may last up to about two years per participant.